Abstract
Alzheimer’s disease (AD) is the most common cause of dementia leading to severe cognitive decline. During the progression of AD, amyloid-β (Aβ) monomers aggregate into neurotoxic soluble oligomeric Aβ that causes cognitive impairments. Our previous study indicates that oral supplementation of taurine at 1000 mg/kg/day significantly ameliorates hippocampal-dependent cognitive deficits in APP/PS1 transgenic AD mouse model. However, Aβ plaques and oligomeric Aβ levels are not affected after administration of taurine and the oral dosage of taurine was relatively high. Thus, in this study, we focused on direct correlation between taurine and oligomeric Aβ, causing memory deficits in a lower oral dosage of taurine, 250 mg/kg/day. We induced AD-like cognitive impairments to adult normal mice and orally administered taurine via drinking water for 10 days. We confirmed that taurine administration improved cognitive deficits in oligomeric Aβ-infusion mice in Y-maze and passive avoidance tests without activity alteration of mice. In addition, we found that taurine directly bound to oligomeric Aβ in surface plasmon resonance analyses. Our results propose that taurine can ameliorate cognitive impairment by directly binding to oligomeric Aβ in oral administration of 250 mg/kg/day for 10 days.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Azuma J, Sawamura A, Awata N, Ohta H, Hamaguchi T, Harada H, Takihara K, Hasegawa H, Yamagami T, Ishiyama T et al (1985) Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol 8(5):276–282
Choi JW, Kim HY, Jeon M, Kim DJ, Kim Y (2012) Efficient access to highly pure beta-amyloid peptide by optimized solid-phase synthesis. Amyloid 19(3):133–137. doi:10.3109/13506129.2012.700287
Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG (2015) Soluble amyloid-beta oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease. Front Cell Neurosci 9:191. doi:10.3389/fncel.2015.00191
Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148(6):1204–1222. doi:10.1016/j.cell.2012.02.040
Huxtable RJ (1992) Physiological actions of taurine. Physiol Rev 72(1):101–163
Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17(6):157–165
Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen AH, Verveer M, de Groot LR, Smith VD, Rangarajan S, Rodriguez JJ, Orre M, Hol EM (2012) GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 7(8):e42823. doi:10.1371/journal.pone.0042823
Kim HY, Kim HV, Yoon JH, Kang BR, Cho SM, Lee S, Kim JY, Kim JW, Cho Y, Woo J, Kim Y (2014) Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer’s disease. Sci Rep 4:7467. doi:10.1038/srep07467
Kim HY, Lee DK, Chung BR, Kim HV, Kim Y (2016) Intracerebroventricular injection of amyloid-beta peptides in normal mice to acutely induce Alzheimer-like cognitive deficits. J Vis Exp 109. doi:10.3791/53308
Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci 24(45):10191–10200. doi:10.1523/JNEUROSCI.3432-04.2004
Matsuyama Y, Morita T, Higuchi M, Tsujii T (1983) The effect of taurine administration on patients with acute hepatitis. Prog Clin Biol Res 125:461–468
Miao J, Zhang J, Zheng L, Yu X, Zhu W, Zou S (2012) Taurine attenuates Streptococcus uberis-induced mastitis in rats by increasing T regulatory cells. Amino Acids 42(6):2417–2428. doi:10.1007/s00726-011-1047-3
Richter L, Munter LM, Ness J, Hildebrand PW, Dasari M, Unterreitmeier S, Bulic B, Beyermann M, Gust R, Reif B, Weggen S, Langosch D, Multhaup G (2010) Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci U S A 107(33):14597–14602. doi:10.1073/pnas.1003026107
Schaffer SW, Azuma J, Madura JD (1995) Mechanisms underlying taurine-mediated alterations in membrane function. Amino Acids 8(3):231–246. doi:10.1007/BF00806821
Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298(5594):789–791. doi:10.1126/science.1074069
Sheng M, Sabatini BL, Sudhof TC (2012) Synapses and Alzheimer’s disease. Cold Spring Harb Perspect Biol 4(5). doi:10.1101/cshperspect.a005777
Acknowledgements
This work was supported by KHIDI (HI14C0466).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media B.V.
About this paper
Cite this paper
Jang, H., Lee, S., Choi, S.L., Kim, H.Y., Baek, S., Kim, Y. (2017). Taurine Directly Binds to Oligomeric Amyloid-β and Recovers Cognitive Deficits in Alzheimer Model Mice. In: Lee, DH., Schaffer, S.W., Park, E., Kim, H.W. (eds) Taurine 10. Advances in Experimental Medicine and Biology, vol 975. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-1079-2_21
Download citation
DOI: https://doi.org/10.1007/978-94-024-1079-2_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-024-1077-8
Online ISBN: 978-94-024-1079-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)